Dermatofibrosarcoma protuberans (DFSP) is a rare sarcoma of soft tissue representing about 1% of all tumors. In addition, DFSP occurs commonly on the trunk and extremities, and only a few cases of DFSP have been observed on the breast. In men, only 11 cases, including this case, have been reported. In this article, we present a case of left breast DFSP that occurred in a 44-year-old man. The physical examination revealed a left breast tender mass, which invaded the skin. The tumor was staged as T4b N0 M0. Mammography and sonography showed a suspect mass of the left breast. The biopsy and immunochemistry permitted the diagnosis of DFSP of the left breast. The patient had a left mammectomy, with free margins. He presents no evident sign of recurrence 7 months later.

Malignant Brenner tumors (MBT) of the ovary are rare diseases, representing 1% of all ovarian cancers and 3-5% of Brenner tumors. They carry a poor prognosis. They generally affect women during the perimenopausal and postmenopausal periods. The standard treatment is surgery; however, the indication of adjuvant chemotherapy remains controversial. The present study aims to report our experience in the treatment of MBT of the ovary, to better characterize this disease. Methods: In this study, a retrospective case series involving four patients diagnosed with MBT of the ovary and treated between 2006 and 2014. Results: Four cases of MBT of the ovary were diagnosed over a seven-year period. The mean age of our patients was 59.3±11.1 years. Three patients were in the menopause period. The tumor was staged as IC in one case, IIC in one case, and IIIC in two cases of the International Federation of Gynecology and Obstetrics classification. All patients underwent surgery, followed by adjuvant chemotherapy. Three patients underwent a loco-regional recurrence that occurred respectively, after nine months in one patient and 11 months in two patients. The treatment was based on chemotherapy combined with surgery in one case. Two patients presented distant metastasis. The treatment consisted of chemotherapy and surgery. The median follows up period was 49.0 (14.0-64.0) months. Conclusion: The treatment approach of MBT of the ovary is not well established since its scarcity and poor prognosis. Thus, more case series and meta-analysis should be conducted.

Introduction Desmoplastic small round cell tumor is a rare malignancy with poor prognosis, affecting young male patients. It frequently presents as a large abdominal mass with widespread peritoneal involvement at diagnosis. In late stages, metastases may be present. Aim We retrospectively reviewed patient characteristics, presenting symptoms, tumor pathology, treatment, and outcome of four patients with desmoplastic small round cell tumor at our institution. Cases presentation The first three cases reported are 32-, 17-, and 30-year-old North African males with intraabdominal desmoplastic small round cell tumor treated by surgery, chemotherapy, and radiation therapy with different follow-ups. The final case is a 16-year-old North African male with ganglionic desmoplastic small round cell tumor but no evidence of a tissue mass. He underwent two lines of chemotherapy with no response. The patient was lost after 2 years of follow-up. In all cases, desmoplastic small round cell tumor was confirmed by presence of t(11,22) (p13,q12) translocation. Conclusion Treatment of desmoplastic small round cell tumor is based on multidisciplinary therapy. Despite high-dose chemotherapy, extensive surgical resection, and radiotherapy, desmoplastic small round cell tumor remains lethal.

Warty squamous cell carcinoma (WSCC), is a rare variant of squamous cell carcinoma that occurs mostly in younger women, but can occur in old women. It is due to human papillomavirus (HPV) infection. This rare entity has been described in several organs such as vulva, cervix, and penis. To the best of our knowledge WSCC of vagina associated with the third-degree of uterine prolapse has never been reported in the literature. We present an exceptional case of WSCC of vagina occurred in a 77-year-old woman with long disease duration. The physical exam found a large ulcer-budding lesion of the middle and lower third of the vagina that depends on the left vaginal wall. The full work-up concluded to stage IVA of FIGO classification, due to the bladder involvement. The patient underwent a hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic node dissection, left partial cystectomy with left ureteral reimplantation and total vaginectomy, followed by adjuvant radiotherapy. The patient had no recurrence during 8 years of regular follow-up. WSCC can express locally aggressive behavior, such we reported; despite it appears to be less aggressive than the typical well-differentiated squamous cell carcinoma. That leads to individualize WSCC from other verruciform neoplasms.

No abstract

Pancreatic metastases are rare, accounting for 2%–3% of pancreatic tumors. The pancreas represents an unusual metastatic site of synovial sarcoma (SS) outside the usual localizations (regional nodes, lung, bone, and liver). The diagnosis is evoked by the personnel medical history of SS and imaging then confirmed by histological examination of the guided pancreatic biopsy. Its therapeutic management is mainly surgical with extensive removal of the lesion. So far only four cases have been reported in the English literature. We reported the case of a male aged 30-year-old who was admitted to our Institute for a local recurrence of SS of the left thigh which was initially treated by surgical excision. The patient underwent a wide surgical excision followed by chemotherapy and radiotherapy. About 15 months later, he experienced a pancreatic metastasis of his SS. He had a caudal splenopancreatectomy with partial resection of the transverse colon followed by chemotherapy. This report highlights the diagnostic difficulties of this rare localization and therapeutic challenge.

Methodology Endometrial tumour was obtained from 21 patients with endometrial cancer and processed into explants. EC-PDEs were then cultured at the air-liquid interface for up to 24 h followed by a further 24 h treatment with Carboplatin and Paclitaxel (CP) or Pembrolizumab and then processed into histology slides. Multiplexed immunofluorescence for Ki67 (proliferation marker), cPARP (apoptosis marker) and CAM 5.2 (tumour mask) was performed for viability studies. Images were then analysed with quantitation of biomarker expression and necrosis area. Results EC-PDEs maintained the histological architecture of the tumour and surrounding TME and remained viable for up to 48 h. Differential drug-responses were detected to single-and dual-agent chemotherapy with positive correlations identified between cell-death and advanced stage (r 2 =0.21, p=0.04), grade (r 2 =0.28, p=0.01) and ESGO risk-categorisation of disease (r 2 =0.49, p<0.01). Cell-death-responses were identified in 61.9% of EC-PDEs following Pembrolizumab-treatment. A third (33.3%) of EC-PDEs responded to both chemotherapy and immunotherapy, 28.5% responded to Pembrolizumab but were resistant to CP, 19% responded to CP but were resistant to Pembrolizumab and 19% of EC-PDEs were resistant to both CP and Pembrolizumab. Conclusion EC-PDEs are a rapid, low-cost pre-clinical model which offers the potential for rapid, personalised pre-clinical drug-response testing. Drug-resistance can be identified in EC-PDEs and EC-PDEs could be used in future to explore the biological effects of immunotherapy and to evaluate predictors of drug response and mechanisms of drug-resistance.

No abstract